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Introduction
The Translational Bioinformatics Conference (TBC) has
been one of the most successful multidisciplinary confer-
ence series in the rapidly emerging field of translational
bioinformatics. The Third Annual TBC (TBC 2013) jointly
held with the Human Genome Variation meeting (HGV
2013) for 5 days at the JW Marriot Hotel, Seoul, South
Korea provided the opportunity to improve the under-
standing of complex and rare diseases and propose new
ways of approaching basic health problems by integrating
genomic and clinical data.
There is growing demand for translational bioinfor-
matics approaches that would allow the heterogeneous
data from basic research to be integrated systematically
into clinical practice in a cohesive and large-scale man-
ner. The expectation is for translational bioinformatics to
integrate and correctly extract clinically actionable infor-
mation from huge data sets at all levels across biological
molecules, subcellular compartments, signaling pathways,
cells, tissues, organs, and systems. Another challenge is
the cultural differences between research scientists and
clinicians and their different value systems.
Linking molecular research and clinical applications will
enormously benefit human health. Applying translational
bioinformatics to next-generation cancer genome sequen-
cing has been very successful in extracting valuable prog-
nostic gene signatures, clinically actionable mutations,
novel network biomarkers, and therapeutic targets across
many types of malignancy, with examples appearing in
areas such as pharmacogenomics, drug developments, and
rare Mendelian disorders. I believe that novel translational
bioinformatics methodologies developed by multidisciplin-
ary stakeholders will rapidly expand into many clinically
disease areas.
Translational bioinformatics for truly personalized
medicine
Personalized medicine involves determining individua-
lized therapies based on the genomic and clinical profiles
of specific individuals, which includes utilizing their
molecular data. While the predictive power of a plethora
of genomic signatures has been successfully demon-
strated, dichotomizing phenotypes based on statistical
significances is problematic due to the presence of major
heterogeneity. In an attempt to realize truly personalized
diagnostics and prognostics, Gardeux et al. (University of
Illinois at Chicago, USA) have proposed a method of
mechanism-level analysis applied to single pairs of sam-
ples, such as tumor vs. matched control, primary tumor
vs. metastases, and before vs. after treatment. Their N-of-
1-pathways predictions not only outperform conventional
methods such as Gene-set Enrichment Analysis (GSEA)
but also identify unique sample/patient mechanisms,
which is a requirement for personalized medicine [1].
Patient-derived xenografts in mouse models have been
widely used in the testing of new anticancer drugs in pre-
clinical evaluations of experimental therapeutics due to
them representing an approximation to the clinical char-
acteristics of patients. These models involve transplanting
human cancer cells into mouse host tissues. However, as
Yang et al. (University of Chicago, USA) pointed out [2],
profiling the mouse and human transcriptomes separately
remains problematic. Yang et al. developed a customized
dual-species array (called the H&M array) that they used
for cross-species and species-specific hybridization with
significantly reduced cross-species hybridization of human
and mouse probes, and were able to determine the ratio of
stromal to cancer cells based on estimations of the cellu-
larity index of mouse/human mRNA contents in vitro.
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Translational biomarkers and pathophysiological
correlates
Biomarkers are indicators of biological states that are useful
for the evaluation of physiological states, pathogenic
processes, and therapeutic responses. While traditional
biomarkers examine the current disease status mainly
based on a single molecule, Li et al. (Soochow University,
China) focused on the development of phase-specific
biomarkers for the progression of prostate cancer through
an integrative analysis of gene expression profiling and
protein interaction networks [3]. They proposed androgen-
receptor nuclear signaling and epidermal-growth-factor-
receptor signaling as biomarkers of prostate cancer
progression.
Shin and Nam (Ajou University, Korea) have expanded
the concept of biomarkers into translational biomarkers
[4]. Their predictor-descriptor approach couples together
two submodules or biomarkers: a predictor and a
descriptor. There is a well-known trade-off when using
machine-learning algorithms between prediction perfor-
mance and the explicit interpretability of the results.
While methodologists tend to put more value on the
novelty and performance of an algorithm, clinicians are
more concerned with how the algorithm obtains a certain
level of performance and its real-world usability.
Shin and Nam proposed a model that predicts the survi-
vability of breast cancer patients using a predictor module,
and then calculates the variable importance of the prog-
nosis factors using a descriptor module, which also makes
it possible to separate patients with similar prognostic pro-
files. They successfully demonstrated the translational
power of the proposed method on the SEER (surveillance,
epidemiology, and end results) cancer incidence database
[5], which is the most comprehensive source of informa-
tion on cancer incidence and survival in the USA.
For discriminating disease phenotypes and discovering
meaningful biomarkers, Han (Fordam University, USA)
proposed applying derivative component analysis (DCA)
to high-dimension serum proteomics data [6]. Compared
with classic principal- and independent-component ana-
lyses, which view each feature as an indecomposable
information unit, DCA examines each feature in a multi-
resolution approach by seeking its derivatives to capture
latent data behavior.
The thousands of genetic variants discovered by gen-
ome-wide association studies (GWASs) have been
shown to explain only a very small proportion of the
underlying genetic variance of complex traits. Gene-
gene interaction analysis is expected to unveil a signifi-
cant proportion of missing heritability information
about complex traits. Kwon et al. (Seoul National Uni-
versity, Korea) have developed an entropy-based algo-
rithm, IGENT (Information theory-based GEnome-wide
gene-gene iNTeraction) [7], that successfully detected
gene-gene interactions underlying bipolar disorder in the
Wellcome Trust Case Control Consortium (WTCCC), as
well as age-related macular degeneration.
Translational bioinformatics for complex diseases
Despite the recent advances in GWASs and next-genera-
tion sequencing technologies associated with the discovery
of thousands of mutations and polymorphisms, the causal
relationship between pathophysiological molecular
mechanisms and therapeutic responses of complex dis-
eases remains unclear. Public databases and numerous
biomedical knowledge resources are invaluable when per-
forming translational bioinformatics research. Prosperi
et al. (University of Manchester, UK) have attempted to fill
this phenome-genome gap by applying a spectrum of lin-
ear and nonlinear machine-learning methods to a large
clinical and genomic attribute set involving complex clini-
cal conditions: asthma, wheeze, and eczema [8]. Grover et
al. (Deakin University, Australia) have attempted to use
existing drugs to treat common complex diseases. They
extracted 1,497 candidate genes for the 7 complex diseases
in the WTCCC GWAS data using a system for predicting
candidate genes, and integrated them with publicly avail-
able drug databases such as the Therapeutic Target Data-
base, PharmGKB, and DrugBank to identify potentially
novel therapeutics for the complex diseases [9].
Methods for high-performance translation
Improved bioinformatics tools and methods are required
for successful translational research. Advanced solutions
have been introduced for well-known bioinformatics pro-
blems. Wang et al. (University of California, San Diego,
USA) have developed a graphics-processing-unit-acceler-
ated massively parallel computing algorithm for miRNA
target identification that was 166 times faster than previous
methods [10]. Joung et al. (Seoul National University,
Korea) detected signatures of inversely correlated expres-
sion profiles of miRNAs and their targets related to cancer
progression [11]. Ren et al. (Ohio State University, USA)
have proposed a layered dynamic programming mapping
(LDPMap) approach that uses indexing and two layers of
dynamic programming techniques to efficiently map each
biomedical term onto a Unified Medical Language System
(UMLS) concept [12]. Mapping medical terms onto
standardized UMLS concepts is a basic step for biomedical
text processing that is hampered by inaccurate query
terms. LDPMap is more effective in querying the UMLS
Metathesaurus for inaccurately spelled medical terms, long
medical terms, and medical terms containing special
characters.
The increasing number of multi-institutional collabora-
tions and demand for data integration makes the detection
and resolution of measurement-unit conflicts challenging.
Samadian et al. (University of British Columbia, Canada)
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utilized existing ontologies and standards for scientific
data representation to build a Semantic Web Service-
based approach to automatic measurement-unit harmoni-
zation [13]. The translated product of translational
bioinformatics may be implemented and carefully evalu-
ated as a clinical decision support system in a hospital
information system setting. Lin et al. (National Taiwan
University, Taiwan) have implemented and evaluated an
automated cellular-phone-based critical-laboratory-value
text-alert system for warfarin therapy at a 2,500-bed ter-
tiary teaching hospital in Taiwan [14]. Ji et al. (UC San
Diego, USA) proposed a logistic regression-based method
for differential privacy against attackers who have auxiliary
information based on both private and public datasets
[15]. The identification of increasing numbers of valid
biomarkers for clinical diagnostics and therapeutics will
lead to more products of translational bioinformatics
being tightly coupled with clinical decision support
systems, which will in turn provide valuable clinical
observations on patients’ functional states and clinician
behaviors, thereby further advancing translational bioinfor-
matics efforts.
The meeting, TBC 2013, has provided the opportunity
for translational bioinformatics researchers to come
together and substantially improve the understanding of
biomolecular and pathophysiological mechanisms,
which will contribute greatly to the development of truly
personalized diagnostics, prognostics, and therapeutics.
I congratulate the speakers and authors at this conference
who are shaping the future of how biomedical informatics
translates into better clinical practice. Many health topics
are increasingly within the scope of translational bioinfor-
matics, including rare and complex human diseases,
cancer, biomarkers, pharmacogenomics, drug reposition-
ing, and clinical decision support systems. As Alan Kay
said, the best way to predict the future of translational
bioinformatics is to invent it.
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